NASDAQ : PHVS
Pharvaris N.V. — Key statistics
Healthcare · Biotechnology · Switzerland
Last price 33.58 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.36B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.35B |
| Enterprise Value | 1.99B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 70.20M |
| Shares Outstanding | 70.20M |
| Shares Change (YoY) | +19.89% |
| Shares Change (QoQ) | +4.24% |
| Owned by Insiders (%) | 2.11% |
| Owned by Institutions (%) | 63.40% |
| Float | 44.13M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 924.70 |
| PB Ratio | 6.85 |
| P/TBV Ratio | 6.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.94 |
| Quick Ratio | 11.82 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,054.74 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -70.46% |
| Return on Assets (ROA) | -42.32% |
| Return on Invested Capital (ROIC) | -46.85% |
| Return on Capital Employed (ROCE) | -60.51% |
| Weighted Average Cost of Capital (WACC) | -9.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.32M |
| Employee Count | 148 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.69M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -2.46 |
| 52-Week Price Change | +51.86% |
| 50-Day Moving Average | 33.66 |
| 200-Day Moving Average | 31.00 |
| Relative Strength Index (RSI) | 59.57 |
| Average Volume (20 Days) | 678,239 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.47M |
| Short Previous Month | 2.01M |
| Short % of Shares Out | 3.51% |
| Short % of Float | 5.59% |
| Short Ratio (days to cover) | 3.40 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -208.30M |
| Pretax Income | -192.58M |
| Net Income | -195.27M |
| EBITDA | -208.12M |
| EBIT | -208.30M |
| Earnings Per Share (EPS) | -$2.99 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 363.63M |
| Total Debt | 769,711 |
| Net Cash | 362.86M |
| Net Cash Per Share | $5.17 |
| Equity (Book Value) | 343.67M |
| Book Value Per Share | 4.90 |
| Working Capital | 342.17M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -173.30M |
| Capital Expenditures | -110,841 |
| Depreciation & Amortization | 176,085 |
| Net Borrowing | -239,827 |
| Free Cash Flow | -173.41M |
| FCF Per Share | -$2.47 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -19.89% |
| Shareholder Yield | -19.89% |
| Earnings Yield | -8.93% |
| FCF Yield | -7.37% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $57.68 |
| Price Target Difference | 72.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |